AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 33668674 — intervention group
Group type: EXPERIMENTAL
Intervention: Cheddar cheese (20 g protein)
Number of subjects: 24
Study 33668674 — intervention group
Group type: COMPARATOR
Intervention: Milk (isonitrogenous amount)
Number of subjects: 24
Study 35006081 — intervention group
Group type: EXPERIMENTAL
Intervention: NoHoW Toolkit (TK)
Number of subjects: 0
Study 35006081 — intervention group
Group type: COMPARATOR
Intervention: Control arm
Number of subjects: 0
Study 33337657 — intervention group
Group type: EXPERIMENTAL
Intervention: Inreach plus mailed outreach
Number of subjects: 12386
Study 33337657 — intervention group
Group type: COMPARATOR
Intervention: Inreach alone
Number of subjects: 12386
Study 35565914 — intervention group
Group type: EXPERIMENTAL
Intervention: Endurance training during rehabilitation
Number of subjects: 32
Study 35565914 — intervention group
Group type: COMPARATOR
Intervention: Control group (no endurance training)
Number of subjects: 32
Study 35649684 — intervention group
Group type: EXPERIMENTAL
Intervention: Explicit sensory retraining (ESR)
Number of subjects: 64
Study 35649684 — intervention group
Group type: EXPERIMENTAL
Intervention: Implicit repeated exposure (IRE)
Number of subjects: 64
Study 35369650 — intervention group
Group type: EXPERIMENTAL
Intervention: TMX-049 200 mg
Number of subjects: 130
Study 35369650 — intervention group
Group type: EXPERIMENTAL
Intervention: TMX-049 40 mg
Number of subjects: 130
Study 35369650 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 130
Study 35369650 — intervention group
Group type: EXPERIMENTAL
Intervention: TMX-049 200 mg and 40 mg
Number of subjects: 130
Study 32187663 — intervention group
Group type: EXPERIMENTAL
Intervention: Perianal block with ropivacaine
Number of subjects: 138
Study 34807241 — intervention group
Group type: EXPERIMENTAL
Intervention: Ciclesonide MDI, 160 μg per actuation, 2 actuations twice a day (total daily dose, 640 μg) for 30 days
Number of subjects: 400
Study 34807241 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 400
Study 34807241 — intervention group
Group type: EXPERIMENTAL
Intervention: Ciclesonide
Number of subjects: 400
Study 32897519 — intervention group
Group type: EXPERIMENTAL
Intervention: Bacillus clausii (Enterogermina®) capsules, 2 × 10^9 spores, three times daily for 2 weeks
Number of subjects: 130
Study 32897519 — intervention group
Group type: COMPARATOR
Intervention: Placebo, three times daily for 2 weeks
Number of subjects: 130
Study 35325392 — intervention group
Group type: EXPERIMENTAL
Intervention: Tailored exercise protocol for CM (TEP‐CM)
Number of subjects: 16
Study 35325392 — intervention group
Group type: EXPERIMENTAL
Intervention: Cervical spinal stabilization exercises (CSSE)
Number of subjects: 16
Study 35325392 — intervention group
Group type: COMPARATOR
Intervention: Both groups (TEP‐CM and CSSE)
Number of subjects: 16
Study 33637948 — intervention group
Group type: EXPERIMENTAL
Intervention: Lifestyle intervention
Number of subjects: 790
Study 33637948 — intervention group
Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 790
Study 33126366 — intervention group
Group type: EXPERIMENTAL
Intervention: Internet-based rehabilitation group (IRG)
Number of subjects: 40
Study 33126366 — intervention group
Group type: COMPARATOR
Intervention: Control group (CG)
Number of subjects: 40
Study 616410548 — intervention group
Group type: EXPERIMENTAL
Intervention: ipragliflozin (50 mg/day)
Number of subjects: 62
Study 616410548 — intervention group
Group type: COMPARATOR
Intervention: control group
Number of subjects: 62
Study 35389028 — intervention group
Group type: EXPERIMENTAL
Intervention: Microneedling group
Number of subjects: 64
Study 35389028 — intervention group
Group type: EXPERIMENTAL
Intervention: Tranexamic acid group (TA 250 mg twice daily)
Number of subjects: 64
Study 35389028 — intervention group
Group type: EXPERIMENTAL
Intervention: Microneedling and tranexamic acid group
Number of subjects: 64
Study 35389028 — intervention group
Group type: EXPERIMENTAL
Intervention: All groups
Number of subjects: 64
Study 33682358 — intervention group
Group type: EXPERIMENTAL
Intervention: HLX03 (adalimumab biosimilar)
Number of subjects: 220
Study 33682358 — intervention group
Group type: COMPARATOR
Intervention: CN-sourced adalimumab (control)
Number of subjects: 220
Study 33682358 — intervention group
Group type: EXPERIMENTAL
Intervention: HLX03
Number of subjects: 220
Study 32646428 — intervention group
Group type: EXPERIMENTAL
Intervention: Trehalose (3.3 g/day)
Number of subjects: 50
Study 32646428 — intervention group
Group type: COMPARATOR
Intervention: Sucrose (3.3 g/day)
Number of subjects: 50
Study 36369671 — intervention group
Group type: EXPERIMENTAL
Intervention: Survivorship care plans (SCPs) delivery arms
Number of subjects: 316
Study 36369671 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified in detail)
Number of subjects: 316
Study 35320642 — intervention group
Group type: EXPERIMENTAL
Intervention: Single high dose of liposomal amphotericin B (10 mg per kilogram of body weight) on day 1 plus 14 days of flucytosine (100 mg per kilogram per day) and fluconazole (1200 mg per day)
Number of subjects: 814
Study 35320642 — intervention group
Group type: COMPARATOR
Intervention: Amphotericin B deoxycholate (1 mg per kilogram per day) plus flucytosine (100 mg per kilogram per day) for 7 days, followed by fluconazole (1200 mg per day) for 7 days (control)
Number of subjects: 814
Study 35320642 — intervention group
Group type: EXPERIMENTAL
Intervention: Single high dose of liposomal amphotericin B
Number of subjects: 814
Study 35320642 — intervention group
Group type: COMPARATOR
Intervention: Amphotericin B deoxycholate (control)
Number of subjects: 814
Study 34129085 — intervention group
Group type: EXPERIMENTAL
Intervention: Maxillary middle meatal antrostomy (MMMA)
Number of subjects: 40
Study 34129085 — intervention group
Group type: COMPARATOR
Intervention: Control (MMMA + frontal sinusotomy)
Number of subjects: 40
Study 34160597 — intervention group
Group type: EXPERIMENTAL
Intervention: Absorbable antibiotic eluting envelope
Number of subjects: 0
Study 32912989 — intervention group
Group type: EXPERIMENTAL
Intervention: Gastric bypass
Number of subjects: 0
Study 32912989 — intervention group
Group type: COMPARATOR
Intervention: Sleeve gastrectomy
Number of subjects: 0
Study 32571414 — intervention group
Group type: EXPERIMENTAL
Intervention: Double layer tragal cartilage‐perichondrium graft (Group A)
Number of subjects: 134
Study 32571414 — intervention group
Group type: COMPARATOR
Intervention: Temporal muscle fascia graft (Group B)
Number of subjects: 134
Study 35882466 — intervention group
Group type: EXPERIMENTAL
Intervention: Digital multiple health behaviour change intervention components (goal setting, increasing motivation, etc.)
Number of subjects: 1500
Study 35882466 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention components)
Number of subjects: 1500
Study 33475824 — intervention group
Group type: EXPERIMENTAL
Intervention: Ipilimumab plus Nivolumab
Number of subjects: 149
Study 33475824 — intervention group
Group type: COMPARATOR
Intervention: Not applicable
Number of subjects: 149
Study 32307155 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral electrolyte solution (OES) administered in milk replacer (MR) and water (3 L at 1300 and 2200 h) for 4 d
Number of subjects: 45
Study 32307155 — intervention group
Group type: COMPARATOR
Intervention: Control group (CON) receiving a small dose of whey (n = 12)
Number of subjects: 45
Study 33550525 — intervention group
Group type: EXPERIMENTAL
Intervention: Device-aided therapies (CSAI, LCIG, DBS)
Number of subjects: 44
Study 32157765 — intervention group
Group type: EXPERIMENTAL
Intervention: Cream A (without tranexamic acid)
Number of subjects: 60
Study 32157765 — intervention group
Group type: EXPERIMENTAL
Intervention: Cream B (with tranexamic acid)
Number of subjects: 60
Study 32157765 — intervention group
Group type: COMPARATOR
Intervention: Placebo cream (Group C)
Number of subjects: 60
Study 36166328 — intervention group
Group type: EXPERIMENTAL
Intervention: Trauma condition (listening to a depiction of sexual assault)
Number of subjects: 105
Study 36166328 — intervention group
Group type: COMPARATOR
Intervention: Control condition (listening to a similar experience without sexual assault)
Number of subjects: 105
Study 32665506 — intervention group
Group type: EXPERIMENTAL
Intervention: Procedural sedoanalgesia (PSA)
Number of subjects: 60
Study 32665506 — intervention group
Group type: COMPARATOR
Intervention: Ultrasound-guided infraclavicular block (ICB)
Number of subjects: 60
Study 32938411 — intervention group
Group type: EXPERIMENTAL
Intervention: Drug Sensitive TB (DS-TB) treatment
Number of subjects: 1178
Study 32938411 — intervention group
Group type: EXPERIMENTAL
Intervention: Multi Drug Resistant Tuberculosis (MDR TB) treatment
Number of subjects: 1178
Study 32938411 — intervention group
Group type: EXPERIMENTAL
Intervention: General TB treatment
Number of subjects: 1178
Study 36004384 — intervention group
Group type: EXPERIMENTAL
Intervention: Dynamic orthosis (night-worn for one year)
Number of subjects: 55
Study 36004384 — intervention group
Group type: COMPARATOR
Intervention: Serial casting (four weeks followed by night splinting)
Number of subjects: 55
Study 34107529 — intervention group
Group type: EXPERIMENTAL
Intervention: Ad26.COV2.S vaccine
Number of subjects: 20
Study 32053141 — intervention group
Group type: EXPERIMENTAL
Intervention: Injection of autologous adipose tissue-derived stromal vascular fraction (ADSVF) into 1 or 2 vocal folds.
Number of subjects: 8
Study 35344012 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-level laser therapy (LLLT)
Number of subjects: 32
Study 35344012 — intervention group
Group type: COMPARATOR
Intervention: Control group (no LLLT)
Number of subjects: 32
Study 33903287 — intervention group
Group type: EXPERIMENTAL
Intervention: Direct-acting oral anticoagulants
Number of subjects: 0
Study 33903287 — intervention group
Group type: COMPARATOR
Intervention: Traditional anticoagulants
Number of subjects: 0
Study 36269738 — intervention group
Group type: EXPERIMENTAL
Intervention: Web-based parenting program entitled 'Making a healthy deal with your child'
Number of subjects: 475
Study 36269738 — intervention group
Group type: COMPARATOR
Intervention: Control condition (existing schoolclass‐based overweight prevention program)
Number of subjects: 475
Study 36269738 — intervention group
Group type: COMPARATOR
Intervention: Control condition
Number of subjects: 475
Study 33675348 — intervention group
Group type: EXPERIMENTAL
Intervention: 5 mg resveratrol
Number of subjects: 30
Study 33675348 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 g resveratrol
Number of subjects: 30
Study 33675348 — intervention group
Group type: COMPARATOR
Intervention: No intervention
Number of subjects: 30
Study 33675348 — intervention group
Group type: EXPERIMENTAL
Intervention: Resveratrol in vitro
Number of subjects: 30
Study 33675348 — intervention group
Group type: EXPERIMENTAL
Intervention: Resveratrol metabolites (mono-sulfates and glucuronides)
Number of subjects: 30
Study 34614330 — intervention group
Group type: EXPERIMENTAL
Intervention: Immediate drainage within 24 hours after randomization
Number of subjects: 104
Study 34614330 — intervention group
Group type: COMPARATOR
Intervention: Postponed drainage until walled-off necrosis was reached
Number of subjects: 104
Study 34614330 — intervention group
Group type: EXPERIMENTAL
Intervention: Immediate drainage
Number of subjects: 104
Study 34614330 — intervention group
Group type: COMPARATOR
Intervention: Postponed drainage
Number of subjects: 104
Study 34971581 — intervention group
Group type: EXPERIMENTAL
Intervention: pegylated interferon alfa-2a in MPN-RC 111
Number of subjects: 280
Study 34971581 — intervention group
Group type: EXPERIMENTAL
Intervention: pegylated interferon alfa-2a in MPN-RC 112
Number of subjects: 280
Study 34971581 — intervention group
Group type: COMPARATOR
Intervention: hydroxyurea in MPN-RC 112
Number of subjects: 280
Study 34971581 — intervention group
Group type: EXPERIMENTAL
Intervention: pegylated interferon alfa-2a
Number of subjects: 280
Study 34971581 — intervention group
Group type: COMPARATOR
Intervention: hydroxyurea
Number of subjects: 280
Study 34971581 — intervention group
Group type: EXPERIMENTAL
Intervention: complete and partial responders
Number of subjects: 280
Study 32934137 — intervention group
Group type: EXPERIMENTAL
Intervention: Pegloticase in combination with Methotrexate (MTX)
Number of subjects: 14
Study 32934137 — intervention group
Group type: EXPERIMENTAL
Intervention: Methotrexate (MTX)
Number of subjects: 14
Study 32934137 — intervention group
Group type: COMPARATOR
Intervention: Pegloticase alone (previously reported)
Number of subjects: 14
Study 32565122 — intervention group
Group type: EXPERIMENTAL
Intervention: 1% THC dose of cannabis
Number of subjects: 16
Study 32565122 — intervention group
Group type: EXPERIMENTAL
Intervention: 4% THC dose of cannabis
Number of subjects: 16
Study 32565122 — intervention group
Group type: EXPERIMENTAL
Intervention: 7% THC dose of cannabis
Number of subjects: 16
Study 32565122 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16
Study 32565122 — intervention group
Group type: EXPERIMENTAL
Intervention: THC plasma levels between 16 ng/mL and 31 ng/mL
Number of subjects: 16
Study 32565122 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive tests
Number of subjects: 16
Study 36092192 — intervention group
Group type: EXPERIMENTAL
Intervention: Intralesional MMR (0.3 ml)
Number of subjects: 60
Study 36092192 — intervention group
Group type: COMPARATOR
Intervention: Subcutaneous MMR (0.5 ml)
Number of subjects: 60
Study 36092192 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 60
Study 33039134 — intervention group
Group type: EXPERIMENTAL
Intervention: Complementary and alternative medicine
Number of subjects: 0
Study 33039134 — intervention group
Group type: COMPARATOR
Intervention: Conventional care
Number of subjects: 0
Study 36308239 — intervention group
Group type: EXPERIMENTAL
Intervention: Manual K‐files
Number of subjects: 45
Study 36308239 — intervention group
Group type: EXPERIMENTAL
Intervention: Manual H‐files
Number of subjects: 45
Study 36308239 — intervention group
Group type: EXPERIMENTAL
Intervention: Kedo‐S Square rotary files
Number of subjects: 45
Study 32503030 — intervention group
Group type: COMPARATOR
Intervention: Control (unexposed to aminophylline)
Number of subjects: 16
Study 32220551 — intervention group
Group type: EXPERIMENTAL
Intervention: Dulaglutide 1.5 mg
Number of subjects: 535
Study 32220551 — intervention group
Group type: COMPARATOR
Intervention: Insulin glargine
Number of subjects: 535
Study 34783998 — intervention group
Group type: EXPERIMENTAL
Intervention: Video-assisted self-reflection during resuscitation
Number of subjects: 10
Study 34783998 — intervention group
Group type: COMPARATOR
Intervention: Self-reflection alone (control group)
Number of subjects: 10
Study 33909172 — intervention group
Group type: EXPERIMENTAL
Intervention: Reduced dose glucocorticoids (GC) for induction and maintenance of remission
Number of subjects: 0
Study 33909172 — intervention group
Group type: EXPERIMENTAL
Intervention: Rituximab (RTX) combined with cyclophosphamide (CYC)
Number of subjects: 0
Study 33909172 — intervention group
Group type: EXPERIMENTAL
Intervention: Mepolizumab (interleukin-5 inhibitor)
Number of subjects: 0
Study 33909172 — intervention group
Group type: EXPERIMENTAL
Intervention: Alternative immunosuppressive agents (e.g. mycophenolate mofetil, abatacept)
Number of subjects: 0
Study 33909172 — intervention group
Group type: EXPERIMENTAL
Intervention: Prolonged course of maintenance treatment
Number of subjects: 0
Study 33909172 — intervention group
Group type: COMPARATOR
Intervention: Plasma exchange
Number of subjects: 0
Study 32928579 — intervention group
Group type: EXPERIMENTAL
Intervention: Whey protein, leucine, and vitamin D supplementation for 12 weeks (Supp group, n=28)
Number of subjects: 56
Study 32928579 — intervention group
Group type: COMPARATOR
Intervention: Dietary counseling for ordinary protein-rich diet (Diet group, n=28)
Number of subjects: 56
Study 32928579 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (Supp and Diet)
Number of subjects: 56
Study 32196748 — intervention group
Group type: EXPERIMENTAL
Intervention: Alcohol consumption (10g/d increase)
Number of subjects: 0
Study 36397118 — intervention group
Group type: EXPERIMENTAL
Intervention: Amino acid blend
Number of subjects: 35
Study 32192596 — intervention group
Group type: EXPERIMENTAL
Intervention: Gonadotropin, clomiphene, or letrozole with IUI for four or fewer treatment cycles
Number of subjects: 900
Study 32192596 — intervention group
Group type: EXPERIMENTAL
Intervention: Clinical androgen markers
Number of subjects: 900
Study 33858493 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard of care plus investigational treatment (IT) with cisternal lavage using urokinase, nimodipine, and Ringer’s solution
Number of subjects: 54
Study 33858493 — intervention group
Group type: COMPARATOR
Intervention: Standard of care only
Number of subjects: 54
Study 35441700 — intervention group
Group type: EXPERIMENTAL
Intervention: Online Healthwise® Driving Decision Aid (DDA)
Number of subjects: 301
Study 35441700 — intervention group
Group type: COMPARATOR
Intervention: Control (web-based information for older drivers)
Number of subjects: 301
Study 34383536 — intervention group
Group type: EXPERIMENTAL
Intervention: Mindfulness training (MT)
Number of subjects: 95
Study 34383536 — intervention group
Group type: EXPERIMENTAL
Intervention: Progressive muscle relaxation (PMR)
Number of subjects: 95
Study 34383536 — intervention group
Group type: COMPARATOR
Intervention: Wait-list condition
Number of subjects: 95
Study 32302056 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 mg dose of macitentan (film‐coated adult formulation)
Number of subjects: 12
Study 32302056 — intervention group
Group type: COMPARATOR
Intervention: 10 mg dose of macitentan (two 5 mg dispersible tablets pediatric formulation)
Number of subjects: 12
Study 36480373 — intervention group
Group type: EXPERIMENTAL
Intervention: Mindfulness and compassion-based intervention (MCBI)
Number of subjects: 63
Study 36480373 — intervention group
Group type: COMPARATOR
Intervention: Active control group (empathy diary)
Number of subjects: 63
Study 33274859 — intervention group
Group type: EXPERIMENTAL
Intervention: 5‐FU@AICRM with green light irradiation
Number of subjects: 0
Study 33274859 — intervention group
Group type: COMPARATOR
Intervention: Group without green light irradiation
Number of subjects: 0
Study 33274859 — intervention group
Group type: COMPARATOR
Intervention: Carmofur (CF, a hydrophobic analog of 5‐FU)‐loaded AICRM (CF@AICRM)
Number of subjects: 0
Study 32899135 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention group (school-based obesity prevention program implemented over two years)
Number of subjects: 36
Study 32899135 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention group (school-based obesity prevention program)
Number of subjects: 36
Study 32899135 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 36
Study 33982418 — intervention group
Group type: EXPERIMENTAL
Intervention: Finely milled 30 mg ER tablets (EDR 6.9)
Number of subjects: 0
Study 33982418 — intervention group
Group type: EXPERIMENTAL
Intervention: Coarsely milled 30 mg ER tablets
Number of subjects: 0
Study 33982418 — intervention group
Group type: EXPERIMENTAL
Intervention: Finely milled 80 mg ER tablets (EDR 4.9)
Number of subjects: 0
Study 33982418 — intervention group
Group type: COMPARATOR
Intervention: Finely milled IR tablets
Number of subjects: 0
Study 33174525 — intervention group
Group type: EXPERIMENTAL
Intervention: 3D-precise breast conformer (3D-BCT group)
Number of subjects: 30
Study 33174525 — intervention group
Group type: COMPARATOR
Intervention: Usual compensator (ST group)
Number of subjects: 30
Study 33174525 — intervention group
Group type: COMPARATOR
Intervention: No compensator (NST group)
Number of subjects: 30
Study 36175907 — intervention group
Group type: EXPERIMENTAL
Intervention: HIIT exercise group
Number of subjects: 52
Study 36175907 — intervention group
Group type: COMPARATOR
Intervention: UC group
Number of subjects: 52
Study 33755051 — intervention group
Group type: EXPERIMENTAL
Intervention: Faecal immunochemical test (FIT) at cut-off values of 2 μg/g
Number of subjects: 9822
Study 33755051 — intervention group
Group type: EXPERIMENTAL
Intervention: Faecal immunochemical test (FIT) at cut-off values of 10 μg/g
Number of subjects: 9822
Study 33755051 — intervention group
Group type: EXPERIMENTAL
Intervention: Faecal immunochemical test (FIT) at cut-off values of 150 μg/g
Number of subjects: 9822
Study 32207414 — intervention group
Group type: COMPARATOR
Intervention: Cervical manual therapy alone (Control)
Number of subjects: 37
Study 32207414 — intervention group
Group type: EXPERIMENTAL
Intervention: Cervical along with thoracic manual therapy (Experimental)
Number of subjects: 37
Study 35707040 — intervention group
Group type: EXPERIMENTAL
Intervention: PiCCO monitoring
Number of subjects: 400
Study 35707040 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 400
Study 34607147 — intervention group
Group type: EXPERIMENTAL
Intervention: Light intensity at 10 lux
Number of subjects: 1800
Study 34607147 — intervention group
Group type: EXPERIMENTAL
Intervention: Light intensity at 30 lux
Number of subjects: 1800
Study 34607147 — intervention group
Group type: EXPERIMENTAL
Intervention: Light intensity at 50 lux
Number of subjects: 1800
Study 34607147 — intervention group
Group type: EXPERIMENTAL
Intervention: Lohmann Brown‐Lite (LB)
Number of subjects: 1800
Study 34607147 — intervention group
Group type: EXPERIMENTAL
Intervention: Lohmann LSL‐Lite (LW)
Number of subjects: 1800
Study 36341464 — intervention group
Group type: EXPERIMENTAL
Intervention: Therapeutic cancer vaccination
Number of subjects: 117
Study 36341464 — intervention group
Group type: EXPERIMENTAL
Intervention: Protein/peptide vaccines
Number of subjects: 117
Study 36341464 — intervention group
Group type: COMPARATOR
Intervention: Randomized trials
Number of subjects: 117
Study 36341464 — intervention group
Group type: COMPARATOR
Intervention: Single group assignment
Number of subjects: 117
Study 36341464 — intervention group
Group type: COMPARATOR
Intervention: Phase 1 trials
Number of subjects: 117
Study 36341464 — intervention group
Group type: COMPARATOR
Intervention: Funding sources
Number of subjects: 117
Study 36341464 — intervention group
Group type: COMPARATOR
Intervention: Geographic location
Number of subjects: 117
Study 36341464 — intervention group
Group type: COMPARATOR
Intervention: Trial outcomes
Number of subjects: 117
Study 35557088 — intervention group
Group type: EXPERIMENTAL
Intervention: ACTH infusion
Number of subjects: 22
Study 35557088 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 22
Study 33096392 — intervention group
Group type: EXPERIMENTAL
Intervention: Tocolysis
Number of subjects: 46
Study 33096392 — intervention group
Group type: COMPARATOR
Intervention: No tocolysis (Control)
Number of subjects: 46
Study 35809011 — intervention group
Group type: EXPERIMENTAL
Intervention: Social interaction intervention (visit with a person with a new ostomy)
Number of subjects: 51